Chong-Kuei Lii

Dr. Chong-Kuei Lii

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Biochemical Pharmacology
Verified
Journal Article
Closed access
CLChia-Yang Lu
Chia-Yang Lu
YYYa-Chen Yang
Ya-Chen Yang
CLChien-Chun Li
Chien-Chun Li
KLKai-Li Liu
Kai-Li Liu
CLChong-Kuei Lii
Chong-Kuei Lii
HCHaw-Wen Chen
Haw-Wen Chen

1 October 2014 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
HCHaw-Wen Chen
Haw-Wen Chen
CHChin-Shiu Huang
Chin-Shiu Huang
CLChien-Chun Li
Chien-Chun Li
ALAi-Hsuan Lin
Ai-Hsuan Lin
YHYu-Ju Huang
Yu-Ju Huang
CLChong-Kuei Lii
Chong-Kuei Lii

9 July 2013 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
CHChin-Shiu Huang
Chin-Shiu Huang
ALAi-Hsuan Lin
Ai-Hsuan Lin
CLCheng-Tzu Liu
Cheng-Tzu Liu
CTChia-Wen Tsai
Chia-Wen Tsai
ICIng-Shr Chang
Ing-Shr Chang
CLChong-Kuei Lii
Chong-Kuei Lii

25 October 2011 in Journal of Natural Products
Verified
Journal Article
Closed access
HCHaw-Wen Chen
Haw-Wen Chen
ALAi-Hsuan Lin
Ai-Hsuan Lin
HCHsing-Chin Chu
Hsing-Chin Chu
CLChien-Chun Li
Chien-Chun Li
CTChia-Wen Tsai
Chia-Wen Tsai
KLKai-Li Liu
Kai-Li Liu

1 February 2015 in Biochemical Pharmacology
Verified
Journal Article
Closed access
CHChin-Shiu Huang
Chin-Shiu Huang
ALAi-Hsuan Lin
Ai-Hsuan Lin
TYTing-Chun Yang
Ting-Chun Yang
KLKai-Li Liu
Kai-Li Liu
HCHaw-Wen Chen
Haw-Wen Chen
CLChong-Kuei Lii
Chong-Kuei Lii

18 February 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
YLYun-Ta Liu
Yun-Ta Liu
HCHaw-Wen Chen
Haw-Wen Chen
CLChong-Kuei Lii
Chong-Kuei Lii
JJJIA HUA JHUANG
JIA HUA JHUANG
CHChin-Shiu Huang
Chin-Shiu Huang
Hsien-Tsung YaoHsien-Tsung Yao
Hsien-Tsung Yao
14-Deoxy-11,12-didehydroandrographolide (deAND), a diterpenoid in Andrographis paniculata (Burm. f.) Nees, acts as a bioactive phytonutrient that can treat many diseases. To investigate the protective effects of deAND on reducing fatty liver disease, male mice were fed a high-fat and high-cholesterol (HFHC) diet without or with 0.05% and 0.1% deAND supplementation. Cholesterol accumulation, antioxidant, and anti-inflammatory activities in liver and liver injury were evaluated after deAND treatment. The results show that deAND treatment for seven weeks reduced plasma alanine aminotransferase activity and lowered hepatic cholesterol accumulation, tumor nuclear factor-α, and histological lesions. The 0.1% deAND treatment reduced HFHC diet-induced apoptosis by lowering the caspase 3/pro-caspase 3 ratio. After 11 weeks of deAND treatment, increased NOD-like receptor protein 3 (NLRP3), capase-1, and interleukin-1β protein levels in liver were suppressed by deAND treatment. In addition, nuclear factor erythroid 2-related factor 2 (Nrf2) mRNA expression, heme oxygenase-1 protein expression, and the activities of glutathione peroxidase and glutathione reductase were increased in mice fed the HFHC diet. However, those activities of antioxidant enzymes or proteins were also upregulated by 0.1% deAND treatment. Furthermore, deAND treatment tended to lower hepatic lipid peroxides. Finally, deAND treatment reversed the depletion of hepatic glutamate level induced by the HFHC diet. These results indicate that deAND may ameliorate HFHC diet-induced steatohepatitis and liver injury by increasing antioxidant and anti-inflammatory activities.